Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07YVK
|
||||
| Former ID |
DCL001006
|
||||
| Drug Name |
Sumanirole
|
||||
| Synonyms |
PNU 95666; U 95666E; PNU-95666; Naphthalene-2-sulfonic acid; [2-[(1R)-1-(methylamino)ethyl]phenyl]methanol; Benzenemethanol, alpha-((1R)-1-(methylamino)ethyl)-, (alphaS)-rel-, 2-naphthalenesulfonate (salt); 2-Naphthalenesulfonic acid, compd with (R*,S*)-alpha-(1-(methylamino)ethyl)benzenemethanol (1:1); 2-Naphthalenesulfonic acid, compd with rel-(alphaS)-alpha-((1R)-1-(methylamino)ethyl)benzenemethanol (1:1)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Parkinson's disease [ICD9: 332; ICD10:G20] | Phase 3 | [1], [2] | ||
| Company |
Pfizer
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C11H13N3O
|
||||
| InChI |
InChI=1S/C11H13N3O/c1-12-8-5-7-3-2-4-9-10(7)14(6-8)11(15)13-9/h2-4,8,12H,5-6H2,1H3,(H,13,15)/t8-/m1/s1
|
||||
| InChIKey |
RKZSNTNMEFVBDT-MRVPVSSYSA-N
|
||||
| CAS Number |
CAS 179386-43-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
14797551, 15195581, 24122573, 44854443, 75621928, 103357480, 103952699, 129144523, 134224983, 134340821, 135261297, 141993172, 160835859, 163097331, 163399818, 163773618, 163846019, 164765184, 172914815, 174006884, 178100776, 198967559, 204431143, 210276636, 223556709, 225376294, 226518850, 242589478
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Agonist | [1] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3949). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.